Trial Profile

Phase II Trial of FANG Autologous Tumor Cell Vaccine in Advanced Melanoma

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 26 May 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bi-shRNAfurin-GM-CSF-loaded tumour cell vaccine (Primary)
Indications Malignant melanoma
Focus Pharmacodynamics; Therapeutic Use
Sponsors Gradalis

Most Recent Events

28 Jul 2017 Status changed from active, no longer recruiting to discontinued.
08 Jan 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov record.
03 Jun 2014 Interim results of 6 studies combined, presented at the 50th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com